Most people know Dr. Sarah Straub (38) from numerous performances as a musician throughout Germany. However, she is also a specialist in frontotemporal dementia and a clinical neuropsychologist at Ulm University Hospital. There, she researches people with dementia and their caregivers. As an artist and as a dementia expert, she sees herself as...
The new Alzheimer's drug Lecanemab is raising great hopes for people with dementia and their caregivers. Very recently, a panel of experts from the European Medicines Agency (EMA) recommended the new active ingredient for treatment – subject to strict conditions. But which patient groups meet the requirements for treatment with Lecanemab? This...
In recent weeks, we have informed you in several parts of our special newsletter SCHLAGLICHT – Medications for Dementia about new dementia drugs and challenges in everyday care. You can reread all published issues at any time in our digiDEM Bavaria newsletter archive: https://digidem-bayern.de/newsletter-archiv/. In the seventh and final issue of our special newsletter SCHLAGLICHT – Medications for Dementia, Michael...
In the sixth edition of our special newsletter SCHLAGLICHT – New Medications Against Dementia, Lisa Laininger, research associate at digiDEM Bayern, discusses the publication by Dr. Jeffrey L. Cummings of the University of Nevada Las Vegas and his colleagues, titled Lecanemab: Appropriate Use Recommendations, in the professional journal The Journal of Prevention of Alzheimer’s…
To what extent are mobile health (mHealth) interventions on smartphones, supported by a coach, suitable for reducing dementia risk? Researchers investigated this with a focus on individuals aged 55 to 75 who had a high risk of dementia. The study included, on the one hand, population groups from Great Britain with a low socioeconomic status, and on the other hand, the general population in the greater area of...
In the fifth edition of our special newsletter, SCHLAGLICHT – New Drugs for Dementia, Anne Keefer, a research associate at digiDEM Bayern, discusses the publication by an international group of researchers led by Prof. Alberto J. Espay of the University of Cincinnati. In the article titled "Recalibrating the Risk-Benefit Profiles of Lecanemab..."
Gender Studies in medicine is a highly relevant societal topic. This is because gender plays an important role in both the development and treatment of diseases. Gender-specific differences are also evident in dementia patients. For example, women develop dementia more often than men and show a different...
The MAKS® therapy was honored with an MSD Health Award 2024. The MAKS® program, consisting of several components, has been proven to help people with mild to moderate dementia maintain their cognitive abilities for as long as possible. The non-pharmacological activation therapy helps to slow the progression of dementia and alleviate its symptoms. For the award...
The risk of developing Alzheimer's dementia is higher for people with mild cognitive impairment (MCI). But to what extent is it possible to predict the progression to Alzheimer's dementia at all? Why can this be an important factor? An accurate prediction could help doctors in their decision-making regarding treatment of...
In the fourth edition of our new special newsletter SCHLAGLICHT – New Drugs for Dementia, Florian Weidinger, research associate at digiDEM Bayern, deals with the publication "The affordability of lecanemab, an amyloid-targeting therapy for Alzheimer’s disease: an EADC-EC viewpoint" by the research team led by Professor Linus Jönsson from the Karolinska Institutet in Sweden. In the journal The Lancet…
